EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil⢠drug-coated balloon (âDCBâ)
Related Questions
What is the revised FY2025 revenue guidance and how does it compare to the previous outlook?
What changes, if any, were observed in operating expenses or margin percentages for the quarter?
Are there any upcoming regulatory milestones, product launches, or contracts that could offset the current revenue decline?
How will the 3% yearâoverâyear revenue decline impact earnings per share expectations for FY2025?
What shortâterm technical implications might this news have on the stockâs price action and trading volume?
Will the revised guidance materially affect the company's valuation multiples (e.g., P/E, EV/Revenue)?
How do Surmodics' Q3 results stack up against peers in the medicalâdevice and inâvitroâdiagnostic space?
What specific factors drove the total revenue decrease in Q3, and are they likely to persist?
What is the projected cashâflow position given the updated fiscalâyear guidance?
How does the performance of the SurVeil⢠drugâcoated balloon segment influence overall profitability?